Posted by Michael Wonder on 19 Dec 2022
Forxiga recommended for approval in the EU by CHMP for symptomatic chronic heart failure
19 December 2022 - f approved, Forxiga will be the first heart failure therapy indicated across the full ejection fraction range with proven mortality reduction
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction including HF with mildly reduced and preserved ejection fraction.
